Cardiology

A new analysis of the phase 3 ATTRibute-CM study, presented at HFSA 2026, may indicate a connection between the number of hospitalizations and mortality risk.

Chen discusses his experience with aortic and cardiac surgery, as well as ongoing research into ways to optimize and improve care.

Hovnanians discusses the benefits of oral versus injectable PCSK9s, as well as the ongoing research to clear enlicitide alone for cardiovascular indications.

Aaron Waxman, MD, PhD, discusses sotatercept’s new indication and recommendation in patients newly diagnosed with PAH at intermediate to high risk.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.

Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.

Joseph Rossano, MD, MS, discusses the SCOUT-HCM trial, mavacamten’s expanded indication, and what it means for pediatric oHCM.

FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.

FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.

Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.

Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.

Get a head start on one of the biggest heart failure conferences of the year with our HFSA 2026 preview.

Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.

Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.

Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.

As AI continues to evolve at a breakneck pace, catch up on some of the ways it’s already been implemented in cardiovascular care.

David Berg, MD, discusses his meta-analysis of 3 major trials of dapagliflozin, which determined its efficacy in reducing cardiovascular death risk.

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.

Kazem Rahimi, MD, discusses his recent IPD analysis highlighting the consistent relative risk reduction of first cardiovascular event with BP-lowering drugs.

Selvanayagam shares his thoughts on whether ICDs’ improvements in sudden cardiac death are worth the reduced quality of life.

Joseph Selvanayagam, MBBS, discusses the potential of implantable cardioverter-defibrillators to reduce sudden cardiac death among younger patients.

Astrid Paul Nordin, MD, PhD, discusses the results of the IDEAL-AF trial, highlighting the efficacy of including LVZ on top of PVI.

Anjali Owens, MD, discusses the long-term extension of the EXPLORER-HCM trial, demonstrating mavacamten’s safety and efficacy up to 5 years after initiation.